Table 1 Patient demographics and baseline characteristics
| Â | GA to fingolimod | Remaining on GA | IM IFN beta-1a to fingolimod | Remaining on IM IFN beta-1a | SC IFN beta-1a to fingolimod | Remaining on SC IFN beta-1a | IFN beta-1b to fingolimod | Remaining on IFN beta-1b |
|---|---|---|---|---|---|---|---|---|
(n = 262) | (n = 74) | (n = 205) | (n = 48) | (n = 196) | (n = 58) | (n = 125) | (n = 39) | |
Mean age (SD), years | 46.3 (9.14) | 44.4 (9.97) | 46.6 (9.90) | 45.1 (10.48) | 45.0 (10.39) | 45.9 (10.25) | 46.3 (10.20) | 47.5 (8.97) |
Women, n (%) | 208 (79.4) | 61 (82.4) | 160 (78.0) | 38 (79.2) | 137 (69.9) | 44 (75.9) | 94 (75.2) | 33 (84.6) |
Race, n (%) | Â | Â | Â | Â | Â | Â | Â | Â |
Caucasian | 222 (84.7) | 64 (86.5) | 165 (80.5) | 36 (75.0) | 160 (81.6) | 44 (75.9) | 94 (75.2) | 31 (79.5) |
Black | 24 (9.2) | 9 (12.2) | 35 (17.1) | 10 (20.8) | 29 (14.8) | 14 (24.1) | 24 (19.2) | 6 (15.4) |
Asian | 2 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.8) | 0 (0.0) |
Native American | 2 (0.8) | 0 (0.0) | 0 (0.0) | 1 (2.1) | 2 (1.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Other | 12 (4.6) | 1 (1.4) | 5 (2.4) | 1 (2.1) | 5 (2.6) | 0 (0.0) | 6 (4.8) | 2 (5.1) |
Mean duration of MS symptoms (SD), years | 13.1 (8.91) | 12.2 (9.36) | 12.0 (7.9) | 11.5 (7.87) | 11.1 (7.89) | 11.4 (8.04) | 12.2 (8.64) | 12.3 (6.78) |
Mean number of MS relapses (SD) | Â | Â | Â | Â | Â | Â | Â | Â |
Previous year | 0.75 (5.53) | 0.84 (3.12) | 0.74 (5.54) | 0.48 (1.66) | 0.76 (6.30) | 0.88 (3.64) | 0.74 (3.90) | 0.62 (1.84) |
Previous 2 years | 1.42 (9.60) | 1.43 (5.81) | 1.20 (7.78) | 0.88 (2.72) | 1.29 (8.54) | 1.45 (5.05) | 1.34 (5.50) | 1.05 (2.83) |
Mean EDSS score (SD) | 2.5 (1.33) | 2.4 (1.35) | 2.5 (1.26) | 2.4 (1.27) | 2.4 (1.35) | 2.3 (1.38) | 2.4 (1.37) | 2.5 (1.39) |